×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CRIS – curis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CRIS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
03:26 pm
cris
Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/15
02:22 am
cris
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... [Yahoo! Finance]
Low
Report
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... [Yahoo! Finance]
11/14
08:22 am
cris
Curis Provides Third Quarter 2024 Business Update [Yahoo! Finance]
Medium
Report
Curis Provides Third Quarter 2024 Business Update [Yahoo! Finance]
11/14
08:00 am
cris
Curis Provides Third Quarter 2024 Business Update
Low
Report
Curis Provides Third Quarter 2024 Business Update
11/13
07:46 am
cris
Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings [Yahoo! Finance]
Medium
Report
Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings [Yahoo! Finance]
11/7
08:00 am
cris
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
Low
Report
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
11/1
04:40 pm
cris
Curis, Inc. (NASDAQ: CRIS) had its price target lowered by analysts at HC Wainwright from $26.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
Curis, Inc. (NASDAQ: CRIS) had its price target lowered by analysts at HC Wainwright from $26.00 to $20.00. They now have a "buy" rating on the stock.
10/29
06:04 am
cris
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
Medium
Report
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
08:06 am
cris
Form 10-Q CURIS INC For: Sep 30
Low
Report
Form 10-Q CURIS INC For: Sep 30
11/13
02:05 pm
cris
Form SC 13G/A CURIS INC Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.
Low
Report
Form SC 13G/A CURIS INC Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.
11/1
04:36 pm
cris
Form SC 13G CURIS INC Filed by: SATTERFIELD THOMAS A JR
Medium
Report
Form SC 13G CURIS INC Filed by: SATTERFIELD THOMAS A JR
10/30
06:02 am
cris
Form 8-K CURIS INC For: Oct 28
Medium
Report
Form 8-K CURIS INC For: Oct 28
10/29
06:03 am
cris
Form FWP CURIS INC Filed by: CURIS INC
Medium
Report
Form FWP CURIS INC Filed by: CURIS INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/27
Form 8-K CURIS INC For: Apr 21
12.4%
2/27 Form 8-K CURIS INC For: Feb 26 11.8%
11/20 Curis, Inc. (NASDAQ: CRIS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.1%
12/6 Form 8-K CURIS INC For: Dec 06 8.6%
11/26 Curis to Present at 31st Annual Piper Jaffray Healthcare Conference 7.3%
10/29 Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019 7.0%
8/13 Curis Hires Industry Veterans to Lead Clinical Development and Regulatory Affairs 4.9%
9/12 Form 4 CURIS INC For: Sep 10 Filed by: Steinkrauss William 3.5%
2/6 Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 3.4%
10/4 Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3.2%
2/27 Form 8-K CURIS INC For: Feb 26 11.8%
11/20 Curis, Inc. (NASDAQ: CRIS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.1%
12/6 Form 8-K CURIS INC For: Dec 06 8.6%
11/26 Curis to Present at 31st Annual Piper Jaffray Healthcare Conference 7.3%
10/29 Curis to Release Third Quarter Financial Results and Hold Conference Call on November 5, 2019 7.0%
8/13 Curis Hires Industry Veterans to Lead Clinical Development and Regulatory Affairs 4.9%
9/12 Form 4 CURIS INC For: Sep 10 Filed by: Steinkrauss William 3.5%
2/6 Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 3.4%
10/4 Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3.2%
TOP News Decliners
8/6
Q2/2019 6/30/2019 EPS -0.220 ZacksConsensus N/A ActVsEst N/A - N/A
-22.0%
12/6 Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study -21.1%
11/5 Q3/2019 9/30/2019 EPS -0.190 ZacksConsensus N/A ActVsEst N/A - N/A -18.8%
3/14 Curis, Inc. (NASDAQ: CRIS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -15.9%
1/7 Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies -12.2%
11/5 Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.6%
3/19 Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%
4/7 Curis to Present at 19th Annual Needham Virtual Healthcare Conference -8.8%
3/6 Form 8-K CURIS INC For: Mar 04 -8.3%
3/12 Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020 -7.3%
12/6 Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study -21.1%
11/5 Q3/2019 9/30/2019 EPS -0.190 ZacksConsensus N/A ActVsEst N/A - N/A -18.8%
3/14 Curis, Inc. (NASDAQ: CRIS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -15.9%
1/7 Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies -12.2%
11/5 Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.6%
3/19 Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%
4/7 Curis to Present at 19th Annual Needham Virtual Healthcare Conference -8.8%
3/6 Form 8-K CURIS INC For: Mar 04 -8.3%
3/12 Curis to Release Fourth Quarter and Year-End 2019 Financial Results and Hold Conference Call on March 19, 2020 -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: